Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The genetic material inside malignant hepatocytes serves as the functional substrate for cytotoxicity induced by localized delivery and decay-mediated emission from yttrium‑90 during radioembolization therapy. Beta particles from Y‑90 cause irreparable damage primarily through induction of single and double-stranded breaks in tumor nuclear DNA[5], resulting in loss-of-function mutations and ultimately triggering apoptosis or necrosis preferentially in rapidly dividing hepatic malignancies while sparing most normal tissue due to limited penetration depth[2][4].
Induction of double-strand breaks via beta irradiation leading to tumor cell death
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA of malignant hepatocyte.